Fig. 1: Kaplan–Meier estimates of progression-free survival (PFS). | Leukemia

Fig. 1: Kaplan–Meier estimates of progression-free survival (PFS).

From: Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

Fig. 1

a All patients with a response of very good partial response (VGPR) or partial response (PR) at study entry, by treatment arm; b patients with VGPR or PR at study entry who did or did not achieve a confirmed deepening of response during or following study treatment, regardless of treatment arm; and c patients with VGPR or PR at study entry who did or did not achieve a confirmed deepening of response during or following study treatment, by treatment arm. Response and progression are as assessed by the independent review committee. CI confidence interval, HR hazard ratio, NE not estimable.

Back to article page